Table 2 ICU and type specific antimicrobial consumption in DOTs, KAMC-R, 2012–2014
| Â | Pediatric general | Pediatric cardiothoracic | Pediatric subtotal | Neonatal | Total |
|---|---|---|---|---|---|
Denominator | |||||
 Patient days | 14,469 | 11,820 | 26,289 | 36,317 | 62,606 |
 Admissions | 1616 | 1492 | 3108 | 1813 | 4921 |
Rates per 1000 patient-days | |||||
 Aminoglycosides | 38.5 | 89.4 | 61.4 | 147.5 | 111.3 |
 Carbapenems | 85.8 | 111.9 | 97.6 | 27.0 | 56.7 |
 Cephalosporins | 237.3 | 299.2 | 265.1 | 98.7 | 168.5 |
 Fluoroquinolones | 23.8 | 19.7 | 22.0 | 1.9 | 10.3 |
 Piperacillin/tazobactam | 91.8 | 24.2 | 61.4 | 1.1 | 26.4 |
 Vancomycin | 185.8 | 112.0 | 152.6 | 44.3 | 89.8 |
 Colistin | 12.3 | 5.9 | 9.4 | 0.4 | 4.2 |
 Caspofungin | 18.2 | 10.7 | 14.8 | 1.1 | 6.9 |
 Amphotericin B | 14.8 | 10.2 | 12.7 | 2.5 | 6.8 |
 Total | 708.3 | 683.2 | 697.0 | 324.5 | 480.9 |
Rates per 100 admissions | |||||
 Aminoglycosides | 34.5 | 70.8 | 51.9 | 295.4 | 141.6 |
 Carbapenems | 76.9 | 88.7 | 82.5 | 54.2 | 72.1 |
 Cephalosporins | 212.4 | 237.0 | 224.2 | 197.6 | 214.4 |
 Fluoroquinolones | 21.3 | 15.6 | 18.6 | 3.8 | 13.1 |
 Piperacillin/tazobactam | 82.2 | 19.2 | 51.9 | 2.2 | 33.6 |
 Vancomycin | 166.3 | 88.7 | 129.1 | 88.7 | 114.2 |
 Colistin | 11.0 | 4.7 | 8.0 | 0.9 | 5.4 |
 Caspofungin | 16.3 | 8.4 | 12.5 | 2.3 | 8.8 |
 Amphotericin B | 13.2 | 8.0 | 10.7 | 5.1 | 8.7 |
 Total | 634.2 | 541.2 | 589.6 | 650.1 | 611.9 |
Average DOT per admission | 6.3 | 5.4 | 5.9 | 6.5 | 6.1 |